News

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...
In results from a Phase Ib study, Hernexeos showed a 75 percent response rate and more than half of patients responded for at least six months.
The assay, developed by ValiRx subsidiary Inaphaea, uses patient-derived cells to predict sensitivity to drugs.
NXC-201 is currently being evaluated in AL amyloidosis within a Phase Ib/II trial, but Immix plans to test it in other, undisclosed serious diseases.
NEW YORK – ProteinQure said on Thursday that the US Food and Drug Administration and Health Canada cleared it to begin a Phase I trial of its lead candidate, the peptide-drug conjugate PQ203, in ...